These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 14560561)
1. Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology. de Cremoux P; Coste J; Sastre-Garau X; Thioux M; Bouillac C; Labbé S; Cartier I; Ziol M; Dosda A; Le Galès C; Molinié V; Vacher-Lavenu MC; Cochand-Priollet B; Vielh P; Magdelénat H; Am J Clin Pathol; 2003 Oct; 120(4):492-9. PubMed ID: 14560561 [TBL] [Abstract][Full Text] [Related]
2. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer. Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934 [TBL] [Abstract][Full Text] [Related]
3. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples. Cibas ES; Hong X; Crum CP; Feldman S Gynecol Oncol; 2007 Mar; 104(3):702-6. PubMed ID: 17150245 [TBL] [Abstract][Full Text] [Related]
4. Resolution of equivocal results with the Hybrid Capture II high-risk HPV DNA test: a cytologic/histologic review of 191 cases. Knoepp SM; Kuebler DL; Wilbur DC Diagn Mol Pathol; 2007 Sep; 16(3):125-9. PubMed ID: 17721319 [TBL] [Abstract][Full Text] [Related]
5. Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. Carozzi FM; Del Mistro A; Confortini M; Sani C; Puliti D; Trevisan R; De Marco L; Tos AG; Girlando S; Palma PD; Pellegrini A; Schiboni ML; Crucitti P; Pierotti P; Vignato A; Ronco G Am J Clin Pathol; 2005 Nov; 124(5):716-21. PubMed ID: 16203283 [TBL] [Abstract][Full Text] [Related]
6. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Castle PE; Schiffman M; Burk RD; Wacholder S; Hildesheim A; Herrero R; Bratti MC; Sherman ME; Lorincz A Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1394-9. PubMed ID: 12433717 [TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus detection: verification with cervical cytology. Matthews-Greer J; Rivette D; Reyes R; Vanderloos CF; Turbat-Herrera EA Clin Lab Sci; 2004; 17(1):8-11. PubMed ID: 15011974 [TBL] [Abstract][Full Text] [Related]
8. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. Dalstein V; Merlin S; Bali C; Saunier M; Dachez R; Ronsin C J Virol Methods; 2009 Mar; 156(1-2):77-83. PubMed ID: 19041893 [TBL] [Abstract][Full Text] [Related]
9. The efficacy of reprocessing unsatisfactory cervicovaginal ThinPrep specimens with and without glacial acetic acid: effect on Hybrid Capture II human papillomavirus testing and clinical follow-up. Agoff SN; Dean T; Nixon BK; Ingalls-Severn K; Rinker L; Grieco VS Am J Clin Pathol; 2002 Nov; 118(5):727-32. PubMed ID: 12428793 [TBL] [Abstract][Full Text] [Related]
11. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Wright TC; Schiffman M; Solomon D; Cox JT; Garcia F; Goldie S; Hatch K; Noller KL; Roach N; Runowicz C; Saslow D Obstet Gynecol; 2004 Feb; 103(2):304-9. PubMed ID: 14754700 [TBL] [Abstract][Full Text] [Related]
12. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets. Getman D; Aiyer A; Dockter J; Giachetti C; Zhang F; Ginocchio CC J Clin Virol; 2009 Jul; 45 Suppl 1():S49-54. PubMed ID: 19651369 [TBL] [Abstract][Full Text] [Related]
13. Anal human papillomavirus testing with Digene's hybrid capture 2 using two different sampling methods. Roka F; Roka J; Trost A; Schalk H; Zagler C; Kirnbauer R; Salat A Dis Colon Rectum; 2008 Jan; 51(1):62-6. PubMed ID: 18030530 [TBL] [Abstract][Full Text] [Related]
14. Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia. Gustavsson I; Juko-Pecirep I; Backlund I; Wilander E; Gyllensten U J Clin Virol; 2009 Jun; 45(2):85-9. PubMed ID: 19451022 [TBL] [Abstract][Full Text] [Related]
15. Comparison of ThinPrep and SurePath liquid-based cytology and subsequent human papillomavirus DNA testing in China. Zhao FH; Hu SY; Bian JJ; Liu B; Peck RB; Bao YP; Pan QJ; Frappart L; Sellors J; Qiao YL Cancer Cytopathol; 2011 Dec; 119(6):387-94. PubMed ID: 21774094 [TBL] [Abstract][Full Text] [Related]
16. Usefulness of combining testing for p16 protein and human papillomavirus (HPV) in cervical carcinoma screening. Ekalaksananan T; Pientong C; Sriamporn S; Kongyingyoes B; Pengsa P; Kleebkaow P; Kritpetcharat O; Parkin DM Gynecol Oncol; 2006 Oct; 103(1):62-6. PubMed ID: 16494930 [TBL] [Abstract][Full Text] [Related]
17. [Detection and typing of human papilloma virus by polymerase chain reaction and hybridization assay in cervical samples with cytological abnormalities]. Ergünay K; Misirlioğlu M; Firat P; Tuncer ZS; Tuncer S; Yildiz I; Ustaçelebi S Mikrobiyol Bul; 2008 Apr; 42(2):273-82. PubMed ID: 18697425 [TBL] [Abstract][Full Text] [Related]
18. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology. Thai H; Rangwala S; Gay T; Keating K; McLeod S; Nazarenko I; O'Neil D; Pfister D; Loeffert D J Clin Virol; 2009 Jul; 45 Suppl 1():S93-7. PubMed ID: 19651375 [TBL] [Abstract][Full Text] [Related]
19. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021 [TBL] [Abstract][Full Text] [Related]
20. Cervical cancer screening in the early post vaccine era. Waxman AG Obstet Gynecol Clin North Am; 2008 Dec; 35(4):537-48; vii. PubMed ID: 19061815 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]